Previous studies have demonstrated that treatment with activin A and TGF-β 1 , members of the TGF-β family, stimulated maturation of mouse bone marrow-derived cultured mast cells (BMMC), which was characterized by morphology and gene expression of mouse mast cell proteases (mmcps). In order to gain a better understanding of activin A-and TGF-β 1 -induced maturation in mast cells, we investigated the genes that were up-regulated in response to treatment with these two members of the TGF-β family. The cDNA microarray analyses indicated that in BMMC, five genes were induced by treatment with 4 nM activin A for 2 h. Tocopherol-associated protein (Tap) was one of the induced genes, and the Tap induction in response to activin A treatment was confirmed by real-time RT-PCR analyses. Treatment with TGF-β 1 at 200 pM but not BMP-2 at 4 nM also increased Tap gene transcript in BMMC. Activin A-induced Tap expression was detected in BMMC but not in RAW264 macrophagelike cells, B16 melanoma cells or P19 embryonic carcinoma cells. Treatment with > 1 μM SB431542, an inhibitor of activin and TGF-β type I receptors ALK4/5, reduced responsiveness of Tap expression to TGF-β 1 , whereas < 0.5 μM SB431542 effectively reduced TGF-β 1 -induced expression of mmcp-1 and mmcp-7. These results suggest that inhibitory effects of SB431542 are different between TGF-β-induced genes. Reporter assays indicated that Tap expression enhances transcription mediated by the activin/TGF-β pathway. Thus, the present results suggest that Tap induction in response to activin/TGF-β occurs predominantly in mast cells and serves as a positive regulator in activin/TGF-β signaling.
Introduction
Mast cells are involved in inflammatory and immediate allergic responses. The multivalent binding of an antigen to receptor-bound IgE and the subsequent aggregation of the high affinity IgE receptor (FcεRI) provide the trigger for activation of mast cells, leading to synthesis and secretion of various enzymes and cytokines related to the immune responses [1] . Mast cells are produced in the bone marrow as progenitor cells.
These committed precursors of mast cells are present in the peripheral blood and invade the target tissues [2] [3] [4] . Mast cells maturate in the target tissue under the regulation of local growth and differentiation factors, resulting in a characteristic morphology with more metachromatic granules and increased expression of mast cell proteases (mcps) [1, 4] . However, our understanding of mast cell maturation at the molecular level remains incomplete.
Activins are dimers of inhibin/activin β subunits and are members of the transforming growth factor-β (TGF-β) superfamily. In common with other members of the TGF-β family such as TGF-βs and bone morphogenetic proteins (BMPs), activins are potent growth and differentiation factors that perform various physiological activities [5, 6] . Previously, we demonstrated that activin A (a homodimer of inhibin/activin βA) stimulated the morphological changes toward maturated mast cells, and increased gene expression of mcps in mouse bone marrow-derived cultured mast cells (BMMC) [7] [8] [9] . As activin A is up-regulated in mast cells in response to activation [10, 11] , it may play a significant role in the immune responses mediated by mast cells. In order to understand activin-induced maturation of mast cells in greater detail, we examined the genes induced in response to activin A treatment in BMMC.
Materials and methods

Materials
Recombinant activin A was kindly provided by Dr. A.F. Parlow through the National Pituitary and Hormone Distribution Program at NIDDK. Purified TGF-β 1 and recombinant BMP-2 were purchased from Becton Dickinson and R&D Systems, respectively. The OMM13K oligonucleotide arrays containing 13,443 70-mer single-stranded oligonucleotides from mouse genes were purchased from the Keck DNA Array Facility at Yale University. SB431542, an ALK4/5 inhibitor [12, 13] , was purchased from TOCRIS. PD98059, a MEK1 inhibitor [14] , and SB203580, a p38 kinase inhibitor [15] , were purchased from Calbiochem. SP600125, a JNK inhibitor [16] , was purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA).
cDNA constructs
Plasmids were obtained as follows: constitutively active ALK5 (ALK5-TD), with Thr 204 replaced by Asp [17] , from Dr. X.-F. Wang, mmcp-7(− 185 to +20)-luc [18] from Drs. Y. Kitamura and E. Morii, PAI-1(− 800 to +76)-luc [19] from Drs. H.F. Lodish and X. Hua, FoxH3 [20] and AR3-luc [21] from Dr. M. Whitman and HA-pcDNA3 expression vector [22] from Dr. N. Inohara and T. Koseki. Human inhibin/activin βA cDNA was subcloned into pcDNA3 using the XhoI site. Mouse Tap cDNA containing BamHI and SalI restriction enzyme sites at the 5′-and 3′-ends, respectively, was subcloned into the BamHI and XhoI sites of HA-pcDNA3 to produce C-terminal HA-tagged Tap.
Animals and cell culture
BALB/c mice were obtained from SLC (Shizuoka, Japan). We used mice with a deletion of Smad3 exon 8, generated through homologous recombination [23] . Litters were produced by mating mice heterozygous for the targeted Smad3 deletion with those from a mixed 129/C57BL/6 background. Genotyping of the offspring was performed as described previously [23] . Mice were cared for according to the principles outlined in the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals [24] .
BMMC were cultured from the bone marrow cells of 6-to 8-week-old mice as described previously [7] . More than 95% of the trypan blue-excluding viable cells were identified as mast cells based on staining with acid toluidine. BMMC were grown in α-MEM containing 10% FBS and 10% pokeweed mitogenstimulated spleen cell-conditioned medium (PWM-SCM vehicle (ethanol) or cycloheximide (0.5 μg/ml) for 15 min prior to treatment with TGF-β 1 (200 pM) for 12 h. RAW264 macrophage-like cells and HepG2 hepatoma cells were provided by the RIKEN Cell Bank, and B16 melanoma cells and P19 embryonic carcinoma cells were provided by the Institute of Development, Aging and Cancer, Tohoku University. RAW264 and HepG2 cells were cultured in DMEM with 10% FBS. P19 cells were cultured in α-MEM with 6% FBS, and B16 cells were cultured in RPMI1640 with 10% FBS. In addition, all cell culture media contained 100 U/ml penicillin and 100 μg/ml streptomycin. Transient transfections were performed using PolyFect (Qiagen) for HepG2 and P19 cells, and SuperFect (Qiagen) for B16 cells.
cDNA microarray
BMMC (2.5 × 10 6 /ml) were treated with or without activin A (4 nM) for 2 h in α-MEM with 10% FBS and 10% PWM-SCM. Total RNA was isolated using an RNA isolation kit (RNeasy, Qiagen). Total RNA (20 μg) was reversetranscribed using oligo-dT and labeled in a total volume of 20 μl using CyScribe First-Strand cDNA Labelling Kit (Amersham Biosciences), according to the manufacturer's protocol. Once the reaction was complete, the template RNA was hydrolyzed by incubation with 2 μl of 2.5 M NaOH for 15 min at 37°C. After adding 10 μl of 2 M HEPES, unconjugated dye was removed using a GFX column (Amersham Biosciences). Cy3-and Cy5-labeled probes were combined and finally resuspended in 5 μl of dH 2 O. The probes were incubated for 2 min at 94°C, followed by incubation on ice for 30 s To block non-specific binding of the poly-T tail in probes, 1.25 μl of oligo A (0.8 mg/ml) was added and incubated for 45 min at 75°C. The glass slide arrays, OMM13K containing 13,443 mouse genes, were prehybridized for 45 min at 50°C in hybridization buffer (Amersham Biosciences) containing 50% formamide, followed by hybridization for 18 h at 43°C. Arrays were washed in 1 × SSC/0.2% SDS for 10 min, followed by two 10-min washes in 0.1 × SSC/0.2% SDS and finally in dH 2 O for 10 s Arrays were dried and scanned at 532 and 635 nm using a GenePix4000A (Axon Instruments, Foster City, CA). Experiments were performed twice using independent cell samples and different dyes were used as the label between experiments. After normalization by linear regression scaling, the ratio of medians was evaluated. Genes that responded to treatment with activin A with ≥1.5-fold increased expression were evaluated further. 
Real-time RT-PCR
Real-time RT-PCR was conducted as described previously [8] . Oligonucleotide primers for mmcp-7 and G3pdh were described as previously [8] . For the Tap and mmcp-1 gene transcripts (GenBank accession numbers BC005759 and NM_008570, respectively), oligonucleotides encoding positions from 785 to 806 and 853 to 834 for Tap, and those from 341 to 365 and 424 to 403 for mmcp-1 were designed. Levels of Tap, mmcp-1, mmcp-7 and G3pdh expression in each sample were determined using the relative standard curve method. The relative amount of DNA of Tap, mmcp-1 and mmcp-7 was expressed as a ratio to that of G3pdh DNA. The Tap, mmcp-1 and mmcp-7 level in BMMC without stimulation with ligands and inhibitors was given a value of 1.
Reporter assay
Luciferase-based reporter assays were conducted as described previously [8] . Cells were transiently transfected with the indicated expression vectors, reporter construct, or a plasmid expressing β-galactosidase (pCMV-βGal). Equal amounts of DNA were transfected in each experiment and adjusted with pcDNA3. Cells were harvested 40 h after transfection. Luciferase activity was normalized against β-galactosidase activity, and the luciferase activity in the cell lysate in the absence of activin βA, ALK5-TD or Tap was assigned a value of 1.
Results
To examine initial events induced by activin A treatment in mast cells, we performed cDNA microarray analyses using BMMC. Results from two independent experiments indicated that only five genes were up-regulated by treatment with activin A (4 nM) for 2 h in both experiments (Table 1) . Activin Ainduction of these genes was confirmed using semi-quantitative RT-PCR (data not shown); in both assays the Tap gene transcript exhibited the greatest response. Tap encodes a protein containing two conserved domains [25] : CRAL/TRIO, which is predicted to form a pocket for binding a small hydrophobic ligand; and GOLD, which is thought to modulate Golgi function or trafficking through protein-protein interaction.
Previous study has shown that in BMMC the activity of activin A depends upon its concentration, i.e., changes in morphology and expression of mmcp are affected by nanomolar concentrations, whereas migration toward activin A is observed at lower concentrations [7] . Competitive RT-PCR analyses indicated that treatment of both BMMC and MC/9 mast cells with activin A at 4 nM but not at 0.1 nM resulted in an increase in Tap transcript (data not shown). In addition, real-time RT-PCR analyses indicated that treatment with TGF-β 1 (200 pM) but not BMP-2 (4 nM) resulted in increased Tap transcript levels (Fig. 1) . In cells unrelated to mast cells, i.e., RAW264, B16 and P19 cells, activin A-induced expression of Tap was not detected, and expression was not induced by the ligands TGF-β 1 or BMP-2 (Fig. 1) .
Time-course changes in Tap gene transcript were next examined in BMMC (Fig. 2A) . Treatment with activin A increased Tap gene transcript within 2 h and the increased gene transcript continued at least for 24 h. Similar to activin A, treatment with TGF-β 1 resulted in a prolonged effect on gene induction of Tap (Fig. 2A) . Up-regulation of Tap by BMP-2 treatment was not seen at any tested time. Because of the limited availability of activin A, the remaining work was carried out by use of TGF-β 1 as the agonist. Previous studies have indicated that TGF-β 1 and activin A elicit similar activities in BMMC including cell growth inhibition, morphological changes, migration and regulation of gene expression [7, 8, 26] . At present activin signaling is indistinguishable from TGF-β signaling at the signaling molecule level of downstream of receptor binding; activin and TGF-β signal via membrane-bound heteromeric serine kinase receptor complexes. Upon ligand binding to respective type II receptor, the type II receptor recruits, phosphorylates and activates the type I receptor (ALK4 for activin, and ALK5 for TGF-β). The activated type I receptor serine kinases phosphorylate Smad2/3, leading to complex formation with Smad4 and regulation of target gene transcription [27, 28] .
In order to determine whether de novo protein synthesis is required for Tap induction, effect of a protein synthesis inhibitor cycloheximide was examined. As shown in Fig. 2B , treatment with cycloheximide did not block the TGF-β 1 -induced Tap expression. The cycloheximide treatment rather increased Tap expression, although responses to TGF-β 1 were smaller in the presence of cycloheximide than in the absence of cycloheximide.
Using BMMC from wild-type and Smad3-null mice and an ALK4/5 inhibitor SB431542, we evaluated the involvement of the type I receptor and Smad3 in TGF-β 1 -induced Tap expression. Previous studies have shown that treatment with TGF-β resulted in the increases in gene transcript of mmcp-1 and mmcp-7 in BMMC [7, 8, 29] . Inhibitory effect of SB431542 on TGF-β 1 -induced Tap gene transcript was compared with that on TGF-β 1 -induced mmcp-1 and mmcp-7 genes. TGF-β 1 -induced Tap gene transcript was partially repressed in the presence of SB431542 in a dose-dependent manner in wild-type BMMC, and the IC 50 concentration of SB431542 was 10.61 ± 3.75 (mean ± S.E.) μM (Fig. 3A) . As compared with the effect of SB431542 on Tap expression, the inhibitor repressed TGF-β 1 -induced mmcp-1 and mmcp-7 genes more efficiently in wildtype BMMC: the IC 50 of SB431542 was 0.45 ± 0.10 μM for mmcp-1 gene and 1.81 ± 0.90 μM for mmcp-7 (Fig. 3B, C) . In Smad3-null BMMC, treatment with TGF-β 1 also increased expression of Tap, mmcp-1 and mmcp-7, although the extent tended to be smaller (Fig. 3) . Effects of SB431542 in Smad3-null BMMC were comparable with those in wild-type BMMC, i.e., less effective inhibition of Tap expression (IC 50 (μM): 7.33 ± 4.79), and efficient inhibition of mmcp-1 (IC 50 (μM): 0.36 ± 0.03) and mmcp-7 (IC 50 (μM): 2.09 ± 0.27).
In addition, we examined the effects of MAP kinase pathway, since activin/TGF-β and MAP kinase pathways are closely related [27, 28] . Although none of the inhibitors (PD98059, SB203580 or SP600125) completely abrogated TGF-β 1 -induced Tap in either wild-type or Smad3-null BMMC, induction was partially repressed by treatment with PD98059 and significantly reduced with SP600125 in BMMC (Fig. 4) . In Smad3-null BMMC, inhibitory effect of kinase inhibitor on TGF-β 1 -induced Tap gene was hardly detected (data not shown).
To elucidate possible role for Tap induced by treatment with activin A and TGF-β 1 , we examined effects of Tap expression on activin/TGF-β signaling using HepG2 cells, B16 cells and P19 cells, which are known to be responsive to these ligands [9, [30] [31] [32] . As Tap is not induced by treatment with these ligands in B16 cells and P19 cells (Fig. 1) , the effects of exogenous Tap on the activin/TGF-β pathway could be clearly evaluated. Luciferase-based reporter assays using mmcp-7-luc, PAI-1-luc and AR3-luc, revealed that Tap enhanced transcription of expression of these reporters induced by expression of activin βA (Fig. 5A) or constitutively active ALK5 (ALK5-TD) (Fig. 5B) . In fact, ALK5-TD-induced transcriptional activation of mmcp-7 was increased with increasing expression of Tap (Fig. 5C ).
Discussion
The present study indicates that: (1) activin A and TGF-β 1 increase expression of Tap in murine mast cells; (2) activin/ TGF-β-induced Tap is limited to mast cells; and (3) the induced Tap acts as a positive modulator for activin/TGF-β signaling. Mast cell-specific up-regulation of Tap in response to activin/ TGF-β explains one of the reasons of diverse physiological activities of members of the TGF-β family irrespective of relatively simple signaling mechanism described above: activin and TGF-β induce modulator genes of themselves in a cell typespecific manner.
Experiments using the protein synthesis inhibitor cycloheximide indicated that de novo synthesis was not required for induction of Tap, suggesting a direct effect of activin/TGF-β. Because members of the TGF-β family phosphorylate and activate various MAP kinases [27, 28] , it is possible that the MAP kinases regulate Tap induction. Experiments using MAP kinase inhibitors indicated the partial inhibition of the Tap induction by treatment with the kinase inhibitor, especially PD98059 and SP600125, in wild-type BMMC but not Smad3-null BMMC, suggesting a functional interaction between the Smad3 pathway and the MAP kinase (in particular the ERK and JNK) pathways.
We observed significant induction of Tap in response to the TGF-β 1 treatment in both Smad3-null and wild-type BMMC, although the level of induction was lower in the former. These results suggest that the involvement of Smad3 in activin/TGF-β-induced Tap is limited, and imply the presence of an as yet unidentified induction pathway. Increased expression of Smad2 has been reported in the liver of Smad3-null mice [33] , and thus, it is possible that expression of Smad2 increases in Smad3-null BMMC, and compensates for the lack of Smad3-mediated signaling. However, we did not observe a significant increase in Smad2 expression in Smad3-null BMMC (data not shown).
Induction of Tap by activin/TGF-β was also inhibited by the ALK4/5 inhibitor SB431542, suggesting that this process is mediated through activated activin/TGF-β receptor complexes. However, the concentration of SB431542 required for efficient inhibition of Tap induction was higher than for either mmcp-1 or mmcp-7. It may be possible that Tap is induced through both an activated ALK4/5-mediated mechanism and an ALK4/5-independent mechanism. Alternatively, it is possible that a limited number of activated ALK4/5 receptor complexes is sufficient for induction of Tap, relative to the requirement for induction of mmcp-1 and mmap-7. However, the latter is unlikely, because the minimum concentration of ligand required for significant induction of mmcp-1 and mmcp-7 was lower than for Tap (data not shown). SB431542 weakly inhibits p38 kinase in vitro [13] , and thus, the partial inhibition of Tap induction at higher SB431542 concentrations may be the result of inhibition of p38 kinase. However, this is also unlikely, since treatment of wild-type BMMC with SB203580 effectively blocked TGF-β 1 -induced activation of p38 (data not shown) but did not inhibit Tap induction significantly. Taken together, the results indicated that Tap induction occurs through both an integrated pathway involving ALK4/5, Smad3 and MAP kinases and an as yet unspecified ALK4/5-independent pathway. Clearly, further definitive studies are needed to elucidate this point.
The Tap has been independently identified as a molecule with activities including binding to α-tocopherol [34] , transport of phosphatidylinositol [35] , transport of squalene for cholesterol biosynthesis [36] , although the physiological role is not clear yet. In addition to these activities, Tap has been recently shown to possess GTPase activity [37] , and to inhibit the phosphoinositide 3-kinase pathway required for growth arrest in cancer cells [38] . Furthermore, CGP-1, a protein with the CRAL/TRIO domain and the GOLD domain, was involved in the Ras signaling pathway in C. elegans [39] . In addition to these activities, the present study revealed that Tap enhanced the activin/TGF-β pathway. This protein with the CRAL/TRIO and GOLD domain may be involved in the regulation of many biological processes in a wide variety of organisms, from nematodes to vertebrates.
